Rice lab’s injectable gel feeds steady dose of drugs to tumor cells
An immunotherapy drug embedded in a slow-release hydrogel invented at Rice University in collaboration with the University of Texas Health Science Center at Houston (UTHealth) appears to be highly effective at killing cancer cells.
STINGel combines a new class of immunotherapy drugs called stimulator of interferon gene (STING) agonists with an injectable hydrogel that releases the drug in a steady dose to activate the immune system to kill cancer cells. It was developed by the Rice lab of chemist and bioengineer Jeffrey Hartgerink and Rice alum Simon Young, an assistant professor of oral and maxillofacial surgery at UTHealth.
In clinical trials, immunotherapy drugs have demonstrated strong cancer-fighting abilities. Research has also found that the drugs are flushed quickly from the body, and current trials require multiple injections.
The new research, which is detailed in Biomaterials, showed that slow-release peptide gels could continuously deliver immunotherapy drugs to tumor sites for long periods of time.
Hartgerink is a pioneer in the development of self-assembling multidomain peptide (MDP) hydrogels, which mimic the body’s extracellular matrix to encourage the growth of cells and vascular systems for tissue repair. The hydrogel is injected as a liquid, turns semisolid inside the body and slowly degrades over time.
The hydrogel in the new study is also welcoming to cells, but when the invaders are cancer cells, they’re in for trouble. Immunotherapy drugs known as cyclic dinucleotides (CDNs) await them inside the gel.
Hartgerink, a professor of chemistry and bioengineering, said the concentration of CDN in the hydrogel is important.
“The normal approach to CDN delivery is simple injection, but this leads to very rapid diffusion of the drug throughout the body and reduces its concentration at the site of the tumor to very low levels,” he said. “Using the same amount of CDN, the STINGel approach allows the concentration of CDN near the tumor to remain much higher for long periods of time.”
STINGel was studied both in lab cultures and in vivo. For the in vivo portion, six groups of 10 rodents each were treated with CDN alone, control collagens alone or with CDN, MDP alone or STINGel (CDN plus MDP). Only one in 10 CDN or collagen plus CDN animals survived 105 days, but six of 10 animals treated with STINGel survived. These also proved resistant to further implantation of cancer cells, meaning their immune systems were trained to successfully identify and destroy both the existing cancer and future occurrence of that cancer, Hartgerink said.
The lab tested more common hydrogels but found that they were unable to provide the same controlled release and also failed to provide an additional benefit over CDN treatment seen in clinical trials. “The MDP hydrogel provides a unique environment for the release of CDN that other gels just can’t match,” Hartgerink said.
“The CDN we used in this study is currently in clinical trials,” he said. “We think that our STINGel approach has the potential to significantly broaden the scope of this powerful immunotherapy drug to a larger range of resistant cancers.”
The Latest on: Cancer immunotherapy
- Hutch science featured at world's premier cancer immunotherapy meeting on November 14, 2018 at 8:32 am
This past weekend, researchers from around the world gathered at the 33 rd annual meeting of the Society for Immunotherapy of Cancer, or SITC, in Washington, D.C. On the minds of everyone there was on... […]
- Immunotherapy Is 'Here to Stay' in Kidney Cancer on November 14, 2018 at 7:38 am
Patients with renal cell carcinoma have more treatment options than ever before, though many questions still remain unanswered, according to Toni Choueiri, M.D. “The field is continuing to evolve, and ... […]
- Dr. Powles on Biomarkers for Immunotherapy in Bladder Cancer on November 13, 2018 at 12:29 pm
Thomas Powles MBBS, MRCP, MD, professor of Genitourinary Oncology, lead, Solid Tumour Research, Barts Cancer Institute, director, Barts Cancer Centre, discusses biomarkers for immunotherapy in bladder ... […]
- Compugen Announces Issuance of U.S. Patent for COM902, Its TIGIT Antibody Product Candidate for Cancer Immunotherapy on November 13, 2018 at 3:00 am
HOLON, Israel, Nov. 13, 2018 /PRNewswire/ -- Compugen Ltd. CGEN, -5.71% a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that a patent for COM... […]
- How can obesity both fuel tumor growth and help new immunotherapy drugs work better? on November 12, 2018 at 4:48 pm
The same obesity-driven process that speeds up cancer growth may also help improve the efficacy of new tumor-killing immunotherapy treatments(Credit: frenta/Depositphotos) Two new studies have ... […]
- Herbst Highlights Next Steps With Immunotherapy in Lung Cancer on November 12, 2018 at 2:29 pm
Immunotherapy has garnered major traction as a treatment approach for patients with lung cancer, but there are still several unanswered questions that need to be addressed in this space, according to ... […]
- Obesity both feeds tumors and helps immunotherapy kill cancer on November 12, 2018 at 12:49 pm
A groundbreaking new study by UC Davis researchers has uncovered why obesity both fuels cancer growth and allows blockbuster new immunotherapies to work better against those same tumors. […]
- Nektar Bounds Higher On 'Promising Contender' In Cancer Immunotherapy on November 12, 2018 at 8:36 am
On the stock market today, Nektar stock jumped 8.7%, to 36.99, in above-average volume. Meanwhile, biotech stocks sank more than 3%. The study looked at an immunotherapy combination using Nektar' NKTR ... […]
- Harpoon Therapeutics snares $70M to focus on cancer immunotherapy on November 12, 2018 at 6:10 am
Harpoon Therapeutics Inc., a South San Francisco company working on engineered proteins that direct infection-fighting T cells to better spot and attack tumor cells, closed a $70 million Series C roun... […]
- Cancer Immunotherapy: The Global Market is Expected to Grow at a CAGR of 13.8% from 2018 to Reach $152.83 Billion by 2024 on November 9, 2018 at 2:49 am
The "Cancer Immunotherapy Market By Type (Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy), Application (Lung, Breast, Multiple Myeloma, Colorectal, Melanoma ... […]
via Google News and Bing News